Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIVON: Triple Therapy With Conventional PPI vs Vonoprazan for H. Pylori Gastritis
NCT03908619Phase 4Unknown
- Sponsor
- Changi General Hospital
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan in Helicobacter pylori infection (4 arms), sponsored by Changi General Hospital. Primary endpoint: Eradication rates of Helicobacter pylori. Status: unknown.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03908619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908619.